Table 1.
Odds ratios for breast cancer incidence by VEGF genotype.
| Polymorphism | Controls (n = 504) | All casesa (n = 501) | In situ cases (n = 107) | Invasive cases (n = 380) | |||
| n (%) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | |
| -2578C/A (rs 699947) | |||||||
| AA | 130 (26.3 %) | 114 (22.9%) | 1.00 (ref.) | 31 (29.0 %) | 1.00 (ref.) | 81 (21.4 %) | 1.00 (ref.) |
| AC | 236 (47.7%) | 245 (49.2%) | 1.18 (0.86–1.61) | 53 (49.5%) | 0.92 (0.55–1.52) | 184 (48.7%) | 1.24 (0.88–1.74) |
| CC | 129 (26.1%) | 139 (27.9%) | 1.25 (0.88–1.77) | 23 (21.5%) | 0.68 (0.37–1.24) | 113 (29.9%) | 1.46 (1.00–2.14) |
| P (for trend) | 0.21 | 0.21 | 0.049 | ||||
| -1154G/A (rs 1570360) | |||||||
| AA | 57 (11.6 %) | 51 (10.3%) | 1.00 (ref.) | 17 (16.0%) | 1.00 (ref.) | 33 (8.8%) | 1.00 (ref.) |
| AG | 227 (46.1%) | 208 (42.0%) | 1.01 (0.66–1.55) | 48 (45.3%) | 0.66 (0.34–1.25) | 152 (40.5%) | 1.14 (0.70–1.84) |
| GG | 208 (42.3%) | 236 (47.7%) | 1.29 (0.84–1.97) | 41 (38.7%) | 0.62 (0.32–1.20) | 190 (50.7%) | 1.64 (1.02–2.64) |
| P (for trend) | 0.083 | 0.24 | 0.007 | ||||
| -634G/C (rs 201963) | |||||||
| GG | 232 (46.4 %) | 221 (44.7%) | 1.00 (ref.) | 56 (52.8%) | 1.00 (ref.) | 161 (42.9%) | 1.00 (ref.) |
| CG | 221 (44.2%) | 222 (44.9%) | 1.05 (0.80–1.37) | 39 (36.8%) | 0.73 (0.46–1.15) | 174 (46.4%) | 1.13 (0.85–1.50) |
| CC | 47 (9.4%) | 52 (10.5%) | 1.18 (0.76–1.83) | 11 (10.4%) | 0.88 (0.42–1.84) | 40 (10.7%) | 1.27 (0.79–2.05) |
| P (for trend) | 0.47 | 0.35 | 0.26 | ||||
| +936C/T (rs 3025039) | |||||||
| TT or CTb | 126 (26.3%) | 128 (26.2%) | 1.00 (ref.) | 39 (38.2%) | 1.00 (ref.) | 86 (23.1%) | 1.00 (ref.) |
| CC | 353 (73.7%) | 360 (73.8%) | 1.02 (0.76–1.36) | 63 (61.8%) | 0.59 (0.37–0.93) | 286 (76.9%) | 1.21 (0.88–1.67) |
| P (for trend) | 0.73 | 0.052 | 0.20 | ||||
| Blood prediction scorec | |||||||
| 0–1 | 31 (6.5 %) | 38 (7.8 %) | 1.00 (ref.) | 11 (10.9 %) | 1.00 (ref.) | 27 (7.3 %) | 1.00 (ref.) |
| 2 | 157 (33.0%) | 131 (27.0%) | 0.72 (0.42–1.22) | 38 (37.6%) | 0.75 (0.34–1.64) | 90 (24.3%) | 0.68 (0.38–1.22) |
| 3 | 198 (41.6%) | 214 (44.1%) | 0.92 (0.55–1.55) | 39 (38.6%) | 0.56 (0.25–1.24) | 166 (44.7%) | 0.99 (0.57–1.75) |
| 4 | 90 (18.9%) | 102 (21.0%) | 0.99 (0.57–1.72) | 13 (12.9%) | 0.39 (0.15–0.98) | 88 (23.7%) | 1.22 (0.67–2.23) |
| Trend OR (95% CI)d | 1.09 (0.94–1.26) | 0.73 (0.57–0.96) | 1.20 (1.02–1.41) | ||||
| P (for trend) | 0.28 | 0.021 | 0.030 | ||||
Odds ratios (ORs) are adjusted for birth-year, year of blood draw, and race/ethnicity. aIncludes 14 cases of unknown stage. bThe TT genotype was carried by eight controls and six cases (two in situ cases and four invasive cases). cSum of -2578C and +936C alleles, which have each been associated with increased blood levels of vascular endothelial growth factor. dOR associated with a 1-point increase in the blood prediction score. CI, confidence interval;